



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

17th May 2022

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Sub: Annual Secretarial Compliance Report for the financial year ended March 31,2022

With reference to the above-mentioned subject and in compliance with the provisions of Regulation 24A of SEBI LODR Amendment Regulations, 2018, read with SEBI Circular dated February 08, 2019, please find enclosed Annual Secretarial Compliance Report of the Company for the financial year ended 31st March 2022.

Kindly take the above information on record.

Thanking you,

Yours faithfully

For GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151

Secretarial Compliance Report of GlaxoSmithKline Pharmaceuticals Limited for the year ended
March 31, 2022

To,
The Board of Directors
GlaxoSmithKline Pharmaceuticals Limited
Dr. Annie Besant Road,
Mumbai 400030

We have examined:

- a) all the documents and records made available to us and explanation provided by **GlaxoSmithKline Pharmaceuticals Limited** ("the listed entity"),
- b) the filings/ submissions made by the listed entity to the stock exchanges,
- c) Website of the listed entity,
- d) any other document/ filing, as may be relevant, which has been relied upon to make this certification,

for the year ended 31st March, 2022 ("Review Period") in respect of compliance with the provisions of :

- a) the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and
- b) the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI");

The specific Regulations (including amendments, modifications from time to time), whose provisions and the circulars/ guidelines issued thereunder, have been examined, include:-

- a) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- b) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;(Not applicable to the company during the review period)
- c) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- d) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018;(Not applicable to the company during the review period)
- e) The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014 and Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; (Not applicable to the company during the review period)

- d) The listed entity has taken the following actions to comply with the observations made in previous reports:

Sr. No.	Observations of the Practicing Company Secretary in the previous reports	Observations made in the secretarial compliance report for the year ended (The years are to be mentioned)	Actions taken by the listed entity, if any	Comments of the Practicing Company Secretary on the actions taken by the listed entity
Not Applicable				

Place: Mumbai

Date: 16.05.2022

Name of the Practicing Company Secretary: P. N. Parikh

For Parikh & Associates
Company Secretaries

Signature: P N
Parikh

Digitally signed by P N Parikh
DN: c=IN, ou=Parikh, postalCode=400104,
st=Maharashtra,
2.5.4.20-01a19173e64d7fecb68f0d4e3d97
190001fdd1d30b113h26d0c0c6d93f0e01,
serialNumber=6450e9f01e973237e1934
97c0e1a9a543aaf2a29f2c9b0c5e69c2f
c, cn=P N Parikh
Date: 2022.05.16 15:51:51 +05'30'

Partner

FCS No.: 327

C P No.: 1228

UDIN: F000327D000324618

PR No.: 1129/2021